Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis Kisqali and Eli Lilly’s Verzenio) are creating new dynamics in the metastatic HR+/HER2– treatment practice. In HER2+ breast cancer, emerging HER2-targeting drugs currently in development are forecasted to enter the market, while current HER2-targeting agents see their sales changing as a result of competition, label expansions, biosimilars entry and new trials leading to changes in treatment guidelines. Furthermore, the approval of AstraZeneca’s Lynparza and anticipated future entry of other PARP inhibitors and immune checkpoint inhibitors will provide more diverse treatment options, especially for triple-negative breast cancer.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Already a Client? Log in to access this report.
is a senior business insights analyst in the oncology team at Decision Resources Group. Before joining DRG, Dr. Liavas worked as a management consultant in healthcare, designing brand and commercial strategy solutions for pharmaceutical companies on a variety of therapy areas, including oncology, immunology and diabetes. He also previously worked as a business & technology consultant at GlaxoSmithKline on digital marketing strategy design and HCP engagement. Dr. Liavas holds a in biological sciences with honours in pharmacology from the University of Edinburgh and a in clinical neuroscience from University College London, focusing on genetic therapies for treating epilepsy.
Alison Isherwood, , joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a in Medical Microbiology, Masters by Research in the Life Sciences and a in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.